

Neurology Medical Group of Diablo Valley
108 La Casa Via
Suite 105
Walnut Creek, CA 94598
Phone: 925-939-9400, Fax: 925-939-1819

Michael John Nelson, MD

Licensure

Primary MD – A 78283, California

Academic Degrees

MD – University of Missouri, Columbia School of Medicine, Columbia, MO	1994 - 1998
BS with Honors - Biology, University of Missouri, Columbia, MO	1990 - 1994

Residencies and Internships

Resident - Neurology, University of Washington, Seattle, WA	1999 - 2002
Internship - Internal Medicine, University of Washington, Seattle, WA	1998 - 1999

Professional Societies

American Medical Association	1999 - present
American Academy of Neurology	1999 – present
American Association of Electrodiagnostic Medicine	1999 – present

Experience

Private Practice of Neurology - Neurology Medical Group of Diablo Valley, Walnut Creek, CA	2002 - present
--	----------------

Awards

Undergraduate – Phi Eta Sigma
Honors College Student
MU Alumni Scholarship
MU Excellence Scholarship

Current Hospital Affiliations

John Muir Medical Center – Walnut Creek, CA
Mt. Diablo Medical Center – Concord, CA

Research Activities

PRINCIPAL INVESTIGATOR

A Prospective, 26-Week, Open-label, Multi-center Study Evaluating the Efficacy And Safety of Exelon (rivastigmine tartrate) 3 – 12 mg/day in Patients with Mild To Moderate Alzheimer's Disease Who Are Responding Poorly to Aricept® (donepezil) Treatment 2003 – 2004

SUBINVESTIGATOR

A double-blind, active and placebo-controlled study of Aggrenox® vs. Clopidogrel + aspirin, with and without Micardis® (PRoFESS) 2003 – present

A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess The Efficacy and Safety of Intravenous NXY-059 In Acute Ischemic Stroke (SAINT II) 2003 – present

A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron® 250µg Subcutaneously Every Other Day with Avonex® 30µg Intramuscularly Once per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated with Avonex® (ABOVE) 2003 – 2005

Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) 2003 – 2005

E2020-A001-319 A 24-Week, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy, Safety and Tolerability of Donepezil Hydrochloride (E2020) in Patients with Dementia Associated with Cerebrovascular Disease 2003– 2004

A Phase III, Multi-center, Randomized, Double-blind, Placebo-controlled, Fixed Dose Response Study Comparing the Efficacy and Safety of Sumanriole versus Placebo in Patients with Early Parkinson's Disease 2003 - 2005

Open-Label, Long-Term, Flexible Dose Study of Safety, Tolerability and Therapeutic Response in Patients with Parkinson's Disease: PNU-95666E 2002 – 2005

A Multicenter, Prospective and Retrospective, Long-Term Observational Study of AVONEX® and Rebif® to Determine the Efficacy, Tolerability, and Safety in Subjects with Relapsing Multiple Sclerosis (MS) (PROOF) 2003 – 2004

Phase I, A Single Rising Dose Study of FK506 Lipid Complex (LCG) in Patients With Recent Ischemic Stroke 2002 – 2004

A Multi-Center, open-label, randomized, 4-way crossover trial of the safety and Efficacy of Tizanidine Hydrochloride Capsules versus Zanaflex® (Tizanidine Hydrochloride) Tablets taken under fed and fasted conditions in patients with Moderate to severe Spasticity 2002